A National Institute for Health and Care Excellence (NICE) – NICE recommends lisocabtagene maraleucel for treating people with large B-cell lymphoma
NICE has released its final guidance recommending Breyanzi (also known as lisocabtagene maraleucel or liso-cel) as a treatment option for individuals with large B-cell lymphoma whose cancer has either not responded to initial treatment or relapsed within...





